Showing 311-320 of 9358 results for "".
- PsO Pipeline Update: First Cohort of Patients Dosed with LNK01004 in Phase Ib Studyhttps://practicaldermatology.com/news/pso-pipeline-update-first-cohort-of-patients-dosed-with-lnk01004-in-phase-ib-study/2461742/The first cohort of psoriatic patients have been dosed in a Phase Ib clinical trial of Lynk Pharmaceuticals Co., Ltd.’s LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patients with mild…
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conferenc…
- Study Seeks to Evaluate V. Dox Technology's Ability to Improve Healing Following HS Surgical Procedurehttps://practicaldermatology.com/news/study-seeks-to-evaluate-v-dox-technologys-ability-to-improve-healing-following-hs-surgical-procedure/2460958/The first patient has been enrolled in a new study using Vomaris Innovations, Inc.’s s bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS). When tunnels develop under the skin in HS, a surgical procedure called deroofing is commonly done. …
- Review Does Not Support Monthly Lab Testing for Oral Isotretinoin Use for Acnehttps://practicaldermatology.com/news/review-does-not-support-monthly-lab-testing-for-oral-isotretinoin-use-for-acne/2458793/A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology. Isotretinoin has been associated with several adverse effects, including terat…
- Aclaris Therapeutics' A-101 Achieves Positive Results in Clinical Trial for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-a-101-achieves-positive-results-in-clinical-trial-for-seborrheic-keratosis/2458989/Aclaris Therapeutics, Inc.’s lead drug candidate A-10 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face in its third Phase II clinical trial. The double-blind, vehicle-controlled Phase 2 clinical trial was designed to evalua…
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report from Polaris Market Research. Most recently valued at $1.163 billion in 2022, the market is expected to reach $5.392 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.6%. "The demand…
- Study: Markers Reveal New Diagnostic Paths in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/study-markers-reveal-new-diagnostic-paths-chronic-spontaneous-urticaria/2462978/A recent study highlighted new diagnostic markers and pathways in chronic spontaneous urticaria (CSU). Researchers publishing in the International Journal of Dermatology included 90 CSU patients and 90 healthy individuals in the analysis. The authors then analyzed markers from diverse metabolic pat…
- Cosmeceutical Market Continues Strong Rise, May Double by 2030https://practicaldermatology.com/news/cosmeceutical-market-continues-strong-rise-may-double-2030/2462662/Advances in technology, an aging population, and increasing interest in natural and organic products are among the trends driving growth in the global cosmeceutical market, according to data from a recent consumer report from SNS Insider, a market research company. The global cosmeceutical market w…
- MHRA Grants Marketing Authorization for Incyte's Opzelura Cream for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescentshttps://practicaldermatology.com/news/mhra-grants-marketing-authorization-for-incytes-opzelura-cream-for-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents/2461838/The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing clearance for Incyte’s Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “Today’s MHRA approval is welcome new…
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a novel, first-in-class, …